Croda International, a UK-based producer of high performance ingredients, has entered a supply alliance with Germany-based Amino.
The partnership is aimed at expanding global access to “high purity”, pharmaceutical-grade amino acids used in drug formulation and biomanufacturing, noted Croda.
It integrates Croda’s global market presence with Amino’s precision manufacturing capabilities.
Amino acids act as excipients in biologic drug formulations and are also used in the manufacture of biologic therapies such as monoclonal antibodies.
Croda intends to launch its BioXPro range of “high-purity” histidine and arginine amino acids in January 2026.
Croda Life Sciences President Thomas Riermeier said: “Our collaboration marks an exciting step forward in expanding the high-quality ingredients available to biopharma developers. By working together, we’re helping customers increase the efficiency of their processes and advance the therapies that will shape the future of patient care.”
The collaboration with Amino adds to a series of recent launches by Croda targeting the biopharmaceutical sector, including Virodex, which is used for viral inactivation and cell lysis, and Super Refined Poloxamer 188, positioned as a shear protectant in cell culture media.
Croda said the agreement supports its broader objective of extending its portfolio of “high-purity” ingredients for use in pharmaceutical formulation and biomanufacturing.
Amino managing director Lutz Thomas added: “The partnership with Croda is both a milestone and a catalyst for Amino’s ambitions in biopharmaceuticals. The combination of Croda’s market reach and our high-purity amino acid production expertise forms a partnership dedicated to meeting specific customer demands.”
Croda is a specialty chemicals company supplying high-performance ingredients for consumer care and life sciences.
Founded in 1925, it operates in 36 countries and focuses on sustainable, bio-based, science-driven solutions.
Amino, headquartered in Frellstedt, manufactures amino acids and related substances for pharmaceutical and nutritional uses, complemented by its AminoVation innovation platform and AMixCo amino acid premix solutions.
